



TSX-V: QPT

TSX-Venture Exchange Listed	Symbol: QPT
Year Founded	1996
Year Listed	1999
Share Capital	\$ 35.6 M
Licensing Fees to Date	\$ 9.6 M
Shares Outstanding	167 M
Options Outstanding	19 M
Shareholder Base	South Korea 42% Canada 25% China 17% US 3% Europe 7 % Insiders 6%

### Recent News

#### Dec 19, 2018

Quest PharmaTech Adopts Amendment to By-laws Requiring Advance Notice of Nomination of Directors

#### Dec 03, 2018

Quest PharmaTech Announces Adoption of Shareholder Rights Plan

#### Nov 28, 2018

Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.

#### Jun 01, 2018

Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting

### Quest Scientific Advisory Board Members

#### Dr. Chris Nicodemus

President & CSO, AIT Strategies, US

#### Dr. Michael A Hollingsworth, Ph.D.

Professor, Eppley Institute, University of Nebraska Medical Center, US

#### Dr. Eric Shi, Ph.D.

Professor, Nanjing Medical University & Associate Dean, Academy of Clinical & Translational Research, Jiangsu Province

#### Dr. Ki-Jun Hwang, Ph.D.

Director of Centre for Research in Bioactive Materials, Chonbuk National University, Korea

#### Dr. Ronald Moore, M.D., Ph.D., FRCS






Cross Cancer Institute, University of Alberta Hospital, Edmonton, Canada

## A Biotechnology Holding Company Developing and Commercializing Products to Improve Quality of Life

## Technologies

- Immuno Oncology:** Combination-treatment strategies based on monoclonal antibodies for tumour specific immunotherapy
- Targeted Cancer Therapy:** Novel target (truncated O-glycans on MUC16) for cancer therapy discovered at University of Nebraska Medical Center
- Transdermal Delivery:** PLGA based proprietary nanoparticles
- SonoLight Technology:** Photodynamic therapy with proprietary photosensitizer

## Unique Business Model Consisting of Five Portfolio Companies

	Company	Highlights	Quest Ownership Info
Cancer Therapies	 OncoQuest INC.	Combinatorial immunotherapy clinical trials are underway for the treatment of ovarian cancer with oregovomab (anti-CA125) and MAb AR20.5 (Anti-MUC1) for pancreatic cancer  Her2/neu IgE preclinical development for metastatic breast cancer	<b>46%</b>
	 OncoVent 昂科生物医药	Development of combinatorial immunotherapeutic products for Greater China region in collaboration with Shenzhen Hepalink	<b>11 %</b>
	 OncoCare Therapeutics	Novel targeted therapy (truncated MUC-16) for pancreatic cancer in collaboration with Fred & Pamela Buffett Cancer Centre, Nebraska	<b>45 %</b>
Dermatology Products	 MADENCO Biosciences Inc.	Dermatology products based on proprietary transdermal delivery technologies	<b>82 %</b>
	 BIOCELTRAN 바이오셀트란	Cosmetic and drug development based on Photodynamic Therapy and/or Protein Transduction Technology	<b>20 %</b>

### OFFICERS AND DIRECTORS

**Dr. Madi R. Madiyalakan, Ph.D.**  
CEO and Director

**Ms. Norma Beauchamp, ICD.D.**  
Director

**Mr. Lorne Meikle, B.A.**  
Director


**Mr. J. Mark Lievonen, C.M., FCPA, FCA, BBA, MBA, LLD**  
Director

**Mr. W. John Meekison, CPA, CMA, P. Log, CIM**  
Director

**Mr. Pierre Vermette, CPA**  
Chief Financial Officer

**Mr. Shawn Lu, CIM, M. Finan**  
Director

# Portfolio Products Under Development



## Company Highlights

- Multiple Products in the Clinic
- Diversified Product Pipeline
- Creating shareholder value with unique therapies and technologies
- Experienced management team
- Portfolio companies in US, South Korea and China
- Global network of collaborators and Investors (US, Korea, Europe and China)
- Considerable scientific and clinical publications in peer reviewed journals
- Extensive patent portfolio

### CONTACT INFORMATION

Dr. Madi R. Madiyalakan, CEO  
 (780) 448-1400 ext.204  
[madi@questpharmatech.com](mailto:madi@questpharmatech.com)